SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX)

SCIENTURE HOLDINGS, INC.

NASDAQ: SCNX (Scienture Holdings, Inc.)

Last update: 5 days ago, 10:10AM

0.701

-0.07 (-9.63%)

Add to watchlist

Previous Close	0.776
Open	0.750
Volume	1,714,505
Avg. Volume (3M)	16,746,321
Market Cap	24,176,780

Price / Earnings (TTM)	1.38
Price / Earnings (Forward)	21.83
Price / Sales	59.78
Price / Book	0.220

52 Weeks Range	0.461 (-34%) — 8.81 (1156%)
Earnings Date	7 Aug 2025 - 11 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Pharmaceutical Retailers (US)	Mixed	Mixed
	Pharmaceutical Retailers (Global)	Mixed	Bearish
Stock	Scienture Holdings, Inc.	-	-

AIStockmoo Score

0.0

Analyst Consensus	0.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	2.5
Technical Oscillators	-0.5
Average	0.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
SCNX	24 M	-	1.38	0.220
HKPD	15 M	-	-	3.00
HITI	268 M	-	-	3.09
WBA	10 B	2.11%	-	1.44
PETS	61 M	-	-	0.560
RDGT	10 M	-	-	0.260

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Sector	Healthcare
Industry	Pharmaceutical Retailers
Investment Style	Small Core
% Held by Insiders	32.59%
% Held by Institutions	1.35%

No data within this time range.

Date	Type	Details
04 Nov 2025	Announcement	SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
23 Oct 2025	Announcement	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
16 Oct 2025	Announcement	SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
08 Oct 2025	Announcement	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
01 Oct 2025	Announcement	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
16 Sep 2025	Announcement	SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
14 Aug 2025	Announcement	Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
13 Aug 2025	Announcement	SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Ex Date	Announcement Date	Payment Date	Details
19 Jul 2024	08 Jul 2024	24 Jul 2024	1.5 Cash
25 Mar 2024	28 Feb 2024	22 Mar 2024	8 Cash

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2024	9.50	2	157.03

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	-34,814.94%
Diluted EPS (TTM)	0.660
Quarterly Revenue Growth (YOY)	-58.70%

Total Debt/Equity (MRQ)	4.70%
Current Ratio (MRQ)	1.05
Operating Cash Flow (TTM)	-7.03 M
Levered Free Cash Flow (TTM)	-6.06 M

Return on Assets (TTM)	-14.99%
Return on Equity (TTM)	-35.92%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)